Gerd has more than 20 years of experience in drug development, operations, quality and program management in the biotech and specialty pharma industry. Prior to joining PellePharm, Gerd helped transform Depomed from a small drug delivery company to a specialty pharma company in the pain and neurology space with over $450 million in annual revenue as the executive team member overseeing the technical operations, project management and quality functions. Previously, Gerd held research and drug development management positions at FibroGen, Inc., and Gryphon Therapeutics. During his time, he led more than a dozen drug development programs ranging from early-stage research to NDA approval and multiple global drug development alliances. He was also part of diligence and deal teams responsible for drug licensing and product acquisition transactions cumulatively valued at over $1.5 billion.

Gerd earned his Ph.D. in chemistry from the University of California at Berkeley. He has published more than 25 papers in peer-reviewed literature and holds multiple patents.